Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenylephrine + tropicamide is a fixed-dose ophthalmic mydriatic combination. Tropicamide is a muscarinic anticholinergic that inhibits cholinergic constriction of the iris sphincter and ciliary muscle, while phenylephrine hydrochloride is an alpha-1 adrenergic agonist that contracts the iris dilator muscle. Together, they produce short-term pupillary dilation for diagnostic ophthalmic procedures and other settings requiring mydriasis. The FDA-approved microdose ophthalmic-spray presentation is marketed in the United States as MydCombi, containing tropicamide 1% and phenylephrine hydrochloride 2.5% and delivered using Eyenovia's Optejet dispenser. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215352s000lbl.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenylephrine + tropicamide.